Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

1.4K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.4K
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

3.0K
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
3.0K
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

1.7K
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.7K
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

2.8K
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
2.8K
Antihypertensive Drugs: Action of β1 Blockers01:17

Antihypertensive Drugs: Action of β1 Blockers

2.2K
β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this,...
2.2K
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers01:22

Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers

1.8K
α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
1.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[INTERVENTIONAL AND SURGICAL TREATMENT OF THE ANGINA PECTORIS RECURRENCE AFTER CORONARY SHUNTING OPERATION].

Klinichna khirurhiia·2016
Same author

[PECULIARITIES OF ROTATIONAL MOTION OF LEFT VENTRICULAR WALLS IN PATIENTS ON MITRAL VALVE INSUFFICIENCY].

Klinichna khirurhiia·2015
Same author

[FEATURES ROTATIONAL MOTION OF LEFT VENTRICULAR WALLS IN PATIENTS WITH AORTAL STENOSIS].

Klinichna khirurhiia·2015
Same author

[LONGITUDINAL SEGMENTAL SHIFT OF THE LEFT VENTRICULUS WALLS IN PATIENTS, SUFFERING THE AORTAL VALVE STENOSIS].

Klinichna khirurhiia·2015
Same author

[DEFORMITY OF LEFT VENTRICLE WALLS IN PATIENTS WITH AORTAL VALVE STENOSIS].

Klinichna khirurhiia·2015
Same author

[Dilated cardiomyopathy: the role of left branch of atrioventricular bundle block in left ventricular walls longitudinal strain indices change].

Klinichna khirurhiia·2015

Related Experiment Video

Updated: Mar 16, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

4.4K

[EFFICACY OF RADIOFREQUENCY ABLATION OF AORTORENAL SYMPATHETIC NODES IN PATIENTS IN ARTERIAL HYPERTENSION].

B V Batsak, B N Gumenyuk, E M Trembovetskaya

    Klinichna Khirurhiia
    |August 13, 2016
    PubMed
    Summary

    Radiofrequency ablation (RFA) of prevertebral sympathetic nodes effectively lowers arterial pressure in hypertensive patients with heart conditions. This minimally invasive procedure offers a stable reduction in blood pressure for those with chronic hypersympathicotony.

    More Related Videos

    Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension
    04:37

    Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension

    Published on: June 6, 2025

    844
    Quantifying Acute Changes in Renal Sympathetic Nerve Activity in Response to Central Nervous System Manipulations in Anesthetized Rats
    06:30

    Quantifying Acute Changes in Renal Sympathetic Nerve Activity in Response to Central Nervous System Manipulations in Anesthetized Rats

    Published on: September 11, 2018

    8.4K

    Related Experiment Videos

    Last Updated: Mar 16, 2026

    Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
    08:35

    Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

    Published on: May 26, 2022

    4.4K
    Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension
    04:37

    Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension

    Published on: June 6, 2025

    844
    Quantifying Acute Changes in Renal Sympathetic Nerve Activity in Response to Central Nervous System Manipulations in Anesthetized Rats
    06:30

    Quantifying Acute Changes in Renal Sympathetic Nerve Activity in Response to Central Nervous System Manipulations in Anesthetized Rats

    Published on: September 11, 2018

    8.4K

    Area of Science:

    • Cardiology
    • Neurology
    • Interventional Radiology

    Context:

    • Hypertension (high blood pressure) poses significant cardiovascular risks.
    • Chronic hypersympathicotony, an overactive sympathetic nervous system, contributes to persistent hypertension.
    • Existing treatments for resistant hypertension may have limitations or side effects.

    Purpose:

    • To evaluate the efficacy of radiofrequency ablation (RFA) targeting prevertebral sympathetic nodes.
    • To assess the impact of RFA on arterial pressure in patients with hypertonic disease and coexisting heart conditions.
    • To determine the long-term effects of RFA on blood pressure control in this patient population.

    Summary:

    • Radiofrequency ablation (RFA) was performed on the prevertebral sympathetic nodes of 36 patients diagnosed with hypertonic disease and concurrent heart conditions.
    • Twelve months post-RFA, patients exhibited a significant average reduction in systolic arterial pressure of 24.3 ± 8.6 mm Hg (3.24 ± 1.15 kPa).
    • Diastolic arterial pressure also decreased by an average of 11.3 ± 3.4 mm Hg (1.51 ± 0.45 kPa) after the procedure.

    Impact:

    • RFA of prevertebral sympathetic nodes demonstrates a potential therapeutic option for managing resistant hypertension.
    • The procedure promotes a stable and sustained lowering of arterial pressure in patients suffering from chronic hypersympathicotony.
    • This study highlights the role of sympathetic nervous system modulation in cardiovascular disease management.